14 research outputs found
Differential Carbohydrate Recognition by Campylobacter jejuni Strain 11168: Influences of Temperature and Growth Conditions
The pathogenic clinical strain NCTC11168 was the first Campylobacter jejuni strain to be sequenced and has been a widely used laboratory model for studying C. jejuni pathogenesis. However, continuous passaging of C. jejuni NCTC11168 has been shown to dramatically affect its colonisation potential. Glycan array analysis was performed on C. jejuni NCTC11168 using the frequently passaged, non-colonising, genome sequenced (11168-GS) and the infrequently passaged, original, virulent (11168-O) isolates grown or maintained under various conditions. Glycan structures recognised and bound by C. jejuni included terminal mannose, N-acetylneuraminic acid, galactose and fucose. Significantly, it was found that only when challenged with normal oxygen at room temperature did 11168-O consistently bind to sialic acid or terminal mannose structures, while 11168-GS bound these structures regardless of growth/maintenance conditions. Further, binding of un-capped galactose and fucosylated structures was significantly reduced when C. jejuni was maintained at 25°C under atmospheric oxygen conditions. These binding differences identified through glycan array analysis were confirmed by the ability of specific lectins to competitively inhibit the adherence of C. jejuni to a Caco-2 intestinal cell line. Our data suggests that the binding of mannose and/or N-acetylneuraminic acid may provide the initial interactions important for colonisation following environmental exposure
Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled multi-Centre trial: TCC:PAINDIP
__Abstract__
Background: The comorbidity of pain and depression is associated with high disease burden for patients in terms
of disability, wellbeing, and use of medical care. Patients with major and minor depression often present
themselves with pain to a general practitioner and recognition of depression in such cases is low, but evolving.
Also, physical symptoms, including pain, in major depressive disorder, predict a poorer response to treatment. A
multi-faceted, patient-tailored treatment programme, like collaborative care, is promising. However, treatment of
chronic pain conditions in depressive patients has, so far, received limited attention in research. Cost effectiveness
of an integrated approach of pain in depressed patients has not been studied.
This article describes the aims and design of a study to evaluate effects and costs of collaborative care with the
antidepressant duloxetine for patients with pain symptoms and a depressive disorder, compared to collaborative
care with placebo and compared to duloxetine alone